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and applied to NHWS averages. Results: RLS patients, when compared to matched 
controls, reported significantly more Health Care Provider (HCP) visits (7.46 vs. 4.42, 
p< .001), Emergency Room (ER) visits (0.45 vs. 0.24, p< .001), and hospitalizations (0.24 
vs. 0.15, p< .001) than controls over the previous 6 month period. RLS patients also 
reported a significantly greater percentage of absenteeism (8.10 vs. 3.92, p< .001), 
presenteeism (26.48 vs. 15.78, p< .001), overall work productivity loss (30.09 vs. 
18.07, p< .001), and activity impairment (46.11 vs. 29.70, p< .001). RLS patients accu-
mulated more direct ($28,871 vs. $17,619, p< .001) and indirect ($10,199 vs. $6,452, 
p< .001) costs annually than controls. For all outcomes reported, an increase in RLS 
severity was significantly correlated with worse health outcomes and increased 
costs. ConClusions: This study sought to quantify the burden that RLS places 
on patients–especially with regard to health care costs—as little is known about 
the economic burden of RLS. Results demonstrate that RLS places a significant 
humanistic and economic burden on patients including loss in work productivity, 
increased health care utilization, and, as a result, greater direct and indirect costs.
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objeCtives: To assess the prevalence of needle phobia and associated clini-
cal practice patterns among patients with MS in Europe and the United States 
(US). Methods: A multicenter retrospective chart-review study of MS patients to 
collect de-identified data on diagnosis, clinical status and treatment approaches. 
Health care providers (HCPs, 95% neurologists) in UK/Germany/France/Italy/Spain 
(EU5) and US were screened for duration of practice (> = 3yrs) and patient volume 
(> = 15 MS patients/month) and recruited from a large panel to be geographically rep-
resentative in each country. Medical charts of the next 10 consecutive MS patients 
were selected by each HCP. Results: 360 HCPs abstracted chart data on 3490 eligible 
MS patients (mean age:39yrs; female:66%). Across markets, 12% (n= 425; EU5:10%; 
US:19%) of patients had needle phobia/did not want to inject. Age, gender, and 
disease severity did not differ compared to patients who did not have injection 
concerns. Among patients with injection concerns, 40% in the EU5 and 30% in the 
US were not currently on treatment, compared with 29% and 20%, respectively, who 
did not have injection concerns. Patients with injection concerns who discontinued 
treatment (13%) had been on their most recent treatment for a mean of 28mo (EU5) 
to 37mo (US). Injection-site reactions, flu-like symptoms, or other tolerability/side-
effects/safety concerns were reported as the reason for discontinuation in 43% 
(EU5) to 50% (US) of patients. Patient refusal was the most common reason that 
patients with injection concerns are not currently receiving treatment (EU5:75%, 
US:65%). Among all relapsing-remitting MS patients in their practice, HCPs noted 
26%(US)/34%(EU5) of patients requesting an oral treatment; among those, only 
20%(US)/13%(EU5) were subsequently switched to oral treatment. ConClusions: 
Needle phobia may add to the humanistic burden of MS and may lead to treatment 
discontinuation and potentially poorer treatment outcomes. Further research is 
warranted to quantify this burden and devise strategies to alleviate it.
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objeCtives: Relapsing-remitting multiple sclerosis (RRMS) patients have a vari-
ety of disease-modifying treatments available with varying risk-benefit trade-offs 
requiring engaging patients in shared decision making, and personalizing patients’ 
treatment by their willingness to accept risk for benefits. This study aimed to quan-
tify the amount of risk RRMS patients were willing to take for three levels of health 
improvement, compare if the acceptable risk varied by baseline disease severity or 
level of improvement gained, and identify predictors of risk attitude to help guide 
treatment choices. Methods: 239 RRMS patients from a neurology clinic completed 
a questionnaire about personal and disease characteristics and a computerized 
standard gamble survey that elicited their utility for current MS health states rela-
tive to improved health states with treatment. From these, patients’ acceptable risks 
of death for three levels of health improvement were calculated. Non-parametric 
statistical analyses were used to compare groups and linear regressions were run to 
identify significant predictors of risk attitude. Results: 199 patients were included 
in the final analysis after removing incomplete or incoherent responses. They were 
predominantly non-Hispanic white females. On average, RRMS patients were willing 
to take an 8.38% risk of death for an improvement in health state. The mean accept-
able risk of death for mild, moderate, and substantial improvement was 5.72%, 
8.03%, and 11.44% (p= 0.0001). Patients with current moderate-severe disease were 
willing to risk significantly more than patients with mild disease (all improve-
ment levels, p< 0.05). Significant predictors of higher risk acceptance included esti-
mated Expanded Disability Status Scale (EDSS) score and non-white ethnicity. Per 
point increase in estimated EDSS, patients were willing to accept 1-2% more risk of 
death. ConClusions: RRMS patients are willing to risk more as their disease wors-
ens and as treatment benefits gained are greater. Patient characteristics, including 
risk-benefit preferences should be used to personalize medicine to the individual.
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reasons for switching and/or non-adherence included: fever (45%), build-up of 
scar tissue from continued injections (35%), not feeling as if their medication is 
working (32%), kidney distress (26%), experiencing a relapse (19%) and insomnia 
(18%). ConClusions: We set out to learn whypatients switched from one drug 
to another, not just information that a switch occurred. The more we know about 
patients’ reasons for their behavior, the more we can actively plan and organize 
patient-centric research, development and outreach. Our results demonstrate that 
using physician-patient interaction data can add tremendous value to outcomes 
researchers and health care decision makers.
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objeCtives: Parkinson´s disease is a neurodegenerative disorder with an esti-
mated incidence of 40-50 cases per 100,00 habitants per year. The EQ-5D health-
related quality of life instrument comprises a health state classification followed 
by a health evaluation using a visual analogue scale (VAS). In this paper, we exam-
ine the correspondence between VAS scores and health state classifications for a 
mexican sample, and identify variables which contribute to determining the VAS 
scores. Methods: A mexican retrospective study of patients having Parkinson´s 
disease from the National Institute of Neurology and Neurosurgery (INNN) provided 
EQ-5D data. Information on seveirty, psychosis and socio-demographic characteris-
tics had been collected using other instruments. A stepwise linear regression model 
was fitted, in which the choice of predictive variables is carried out by an automatic 
procedure. VAS score was the dependent variable, independent variables comprised 
EQ-5D health state classifications, severity, age, psychosis and socio-demographic 
characteristics. Results: 248 mexican patients were evaluated in the model: 54% 
were male and 46% were female; also 74.2% had low severity, 18.5% had moderate 
severity and 7.3% had advanced severity; in addition, 16.5% of pacientes hadn´t 
formal education compared to 21% of patients having college or higher educa-
tion. Finally, 60.1% of patients were 60 years old or more when the retrospective 
study was performed. EQ-5D health state classifications (personal hygiene, mobil-
ity, anxiety/depression) were statistically significant fitting the model. In addition, 
VAS score was influenced also by the subject’s educational attainment (p-value< .05, 
R2= 19). Changes in VAS score were explained by changes in both EQ-5D mobility and 
anxiety. ConClusions: In this sample, EQ VAS scores were predictable from the 
EQ-5D health state classifications (personal higiene, mobility and anxiety/depres-
sion), although there also existed another variable (educational attainment) which 
contributed systematically and independently towards determining such scores.
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objeCtives: Parkinson´s disease is a neurodegenerative disorder with an estimated 
incidence of 40-50 cases per 100,00 habitants per year. The EQ-5D is a brief, multi-
attribute, preference-based health status measure. In this paper, we describe the 
development of a statistical model for generating mexican sample-based EQ-5D 
utility index for patients having Parkinson´s disease. Methods: A mexican retro-
spective study of patients having Parkinson´s disease from the National Institute 
of Neurology and Neurosurgery (INNN) provided EQ-5D health state classification. 
Respondents valued EQ-5D health states using the visual analogue score (VAS) 
method. A linear regression model was fitted, VAS score was the dependent vari-
able and the independent variables comprised EQ-5D health state classifications. 
Finally, an algorithm for computing the utility index was performed from the model 
output. Results: 248 mexican patients were evaluated in the model: 54% were male 
and 46% were female; also 74.2% had low severity, 18.5% had moderate severity and 
7.3% had advanced severity; in addition, 16.5% of pacientes hadn´t formal education 
compared to 21% of patients having college or higher education. Finally, 60.1% of 
patients were 60 years old or more when the retrospective study was performed. 
Our model for the EQ-5D included ordinal terms to capture the effect of departures 
from perfect health as well as interaction effects. After fitting the model, the utility 
index for Parkinson´s disease reported was 0.8694. ConClusions: The model best 
predicts the values for observed health states. The resulting preference estimates 
represent a significant enhancement of the EQ-5D’s utility for health status assess-
ment and economic analysis in Parkinson´s disease for mexican patients.
PND39
the humaNistic aND ecoNomic burDeN of restless legs syNDrome
Durgin T.1, Witt E.A.2, Fishman J.1
1UCB Pharma, Smyrna, GA, USA, 2Kantar Health, Princeton, NJ, USA
objeCtives: To examine health status, health care resource use, work productivity, 
and associated costs for patients with restless legs syndrome (RLS) compared to a 
control cohort and the association between these variables and increased symptom 
severity. Methods: The sample was drawn from the 2012 National Health and 
Wellness Survey (NHWS; n = 71,157) an annual survey of US adults. Respondents 
reporting a diagnosis of RLS (n = 2,392; 56.9% women, Mean age 55.9 years) were 
propensity score matched on demographics to an equally-sized non-diagnosed 
comparison group. Patients self-reported RLS symptom severity (mild, moderate, 
severe), health care resource use and work productivity. Costs of health care use 
and work productivity loss were extrapolated from existing governmental estimates 
